Latest Articlesddd
In the NEWS: Coronavirus Yesterday the CDC announced the first US case of coronavirus which has …
Forty Seven On December 21, 2018 Prohost picked Forty Seven (FTSV) at $16.95 adding it to …
Outperforming Prohost Picks January 16, 2020 at 11:30 am EST MRNA Trading at $21.35 UP $1.01 …
Nektar in the NEWS The FDA's Anesthetic and Analgesic Advisory Committee (AADPAC) and Drug Safety and Risk …
A Comprehensive Essay Part 2 In Part 1 of our comprehensive essay series Vertex Pharmaceuticals (VRTX) …
XBiotech XBiotech (XBIT), headquartered in Austin, Texas, develops innovative proprietary manufacturing technology that reduces the cost and …
Nektar Therapeutics and Bristol-Myers Squibb Agreement Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) announced their agreement …
Moderna's mRNA Vaccine Today could be one of the important early days as Moderna (MRNA) succeeded …
A Comprehensive Essay Part 1 Yes, we have stories to tell about some of our picked …
Coming Soon at Prohost Biotech We have stories to tell about our picked stocks which we …
Prohost Letter #438 End of the Year Issue 2019 Happy New Year 2020 The NASDAQ reached …
Cassava Sciences Stock is Rallying Cassava Sciences (SAVA) stock closed on Friday, December 27, 2019 at …
Cassava Sciences: PTI-125 for Alzheimer's Disease Cassava Sciences (SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, …
The Week in Review #48 Holiday Edition ******************** Merry Christmas and Happy Hanukkah! We Wish You …
More from the Prohost Portfolio with Our Observations Gilead (GILD) has cash and new products reaching …
Regenxbio Results from RGX-121 for MPSII Regenxbio (RGNX) announced interim data from Phase I/II trial of …
Amylyx Pharmaceuticals With the advancement of biological sciences, and increased information about the pathways of diseases, …
From Amarin Amarin (AMRN) announced the U.S. FDA has approved a new indication and label expansion for …
Exelixis Positive Results from IMspire 150 Exelixis (EXEL) announced positive results from IMspire 150; the phase 3 …
Ionis Pharmaceuticals
Ionis Pharmaceuticals (IONS) announces a private placement of $507.5 million principal amount of 0.125% convertible …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
